Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Université de Sherbrooke

$50,000.00

Macrocyclic Inhibitors of the SARS-CoV-2 / ACE-2 Interaction in COVID-19

FY 2020-21

Summary
The goal of this proposal is to develop and optimize new drugs able to prevent coronavirus entry into human airway cells. This project is a collaboration between Université de Sherbrooke and Nuchem Therpeutics (Montreal), University of British Columbia (Vancouver) and Collège de Shawinigan. Through the current pandemic, we have to humbly recognize that we were ill-prepared for such outbreak. Its human, economic and strategic impacts are global and will be durable. This pandemic has nevertheless mobilized the scientific community at all levels to better understand the mechanisms involved in SARS-CoV-2 infection and find solutions to manage the disease and its consequences. In terms of treatment options, short-term solutions in the form of repurposed drugs or biologics (e.g., antibodies) could possibly provide much-needed relief. This is an emergency response and every possible drug already on the market or in clinical development is being tested. However these drugs were not optimized for SARS-CoV-2. In the mid-term, vaccination will hopefully provide a means to prevent novel infections and carries hopes for large scale prevention. Thus, there is currently no drug specifically targeting SARS-CoV-2, and little know-how to be implemented in potential future coronavirus epidemics. Ultimately, these efforts are expected to lead to a class of drugs known as entry inhibitors, with the potential to not only cure patients infected by SARS-CoV-2 by stopping the virus from penetrating cells, but also to prevent healthy people from being infected. This proposal exploits novel macrocyclic inhibitors targeting protein-protein interactions between the Spike protein of SARS-CoV-2, and its host receptor, ACE-2. The first step of the project is to computationally design macrocycles that mimic motifs found on two proteins involved in viral entry. The second step is to synthesize them, while the third is to test their ability to block the interaction between the two proteins, and demonstrate their ability to block viral infection in cells. _x000d_Le but de ce projet est de développer et optimiser des médicaments capables de bloquer l'entrée du coronavirus dans les cellules respiratoires. Ce projet est aussi une collaboration entre chercheurs de l'Université de Sherbrooke, Nuchem Therapeutics (Mont
Program
Alliance Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
555123-2020
Name nom
Grandbois, Michel
Department département
Pharmacologie-physiologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Macrocyclic Inhibitors of the SARS-CoV-2 / ACE-2 Interaction in COVID-19
Keyword
NSERC
Application summary
The goal of this proposal is to develop and optimize new drugs able to prevent coronavirus entry into human airway cells. This project is a collaboration between Université de Sherbrooke and Nuchem Therpeutics (Montreal), University of British Columbia (Vancouver) and Collège de Shawinigan. Through the current pandemic, we have to humbly recognize that we were ill-prepared for such outbreak. Its human, economic and strategic impacts are global and will be durable. This pandemic has nevertheless mobilized the scientific community at all levels to better understand the mechanisms involved in SARS-CoV-2 infection and find solutions to manage the disease and its consequences. In terms of treatment options, short-term solutions in the form of repurposed drugs or biologics (e.g., antibodies) could possibly provide much-needed relief. This is an emergency response and every possible drug already on the market or in clinical development is being tested. However these drugs were not optimized for SARS-CoV-2. In the mid-term, vaccination will hopefully provide a means to prevent novel infections and carries hopes for large scale prevention. Thus, there is currently no drug specifically targeting SARS-CoV-2, and little know-how to be implemented in potential future coronavirus epidemics. Ultimately, these efforts are expected to lead to a class of drugs known as entry inhibitors, with the potential to not only cure patients infected by SARS-CoV-2 by stopping the virus from penetrating cells, but also to prevent healthy people from being infected. This proposal exploits novel macrocyclic inhibitors targeting protein-protein interactions between the Spike protein of SARS-CoV-2, and its host receptor, ACE-2. The first step of the project is to computationally design macrocycles that mimic motifs found on two proteins involved in viral entry. The second step is to synthesize them, while the third is to test their ability to block the interaction between the two proteins, and demonstrate their ability to block viral infection in cells. _x000d_Le but de ce projet est de développer et optimiser des médicaments capables de bloquer l'entrée du coronavirus dans les cellules respiratoires. Ce projet est aussi une collaboration entre chercheurs de l'Université de Sherbrooke, Nuchem Therapeutics (Mont
Université de Sherbrooke - $50,000 Grant (2020-21) | Canada Spends